SCHEMBL3310105

SCHEMBL3310105

Cc1ccc(Cl)c(C(=O)C=C(O)C(=O)O)c1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLCN2 P51788 2/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HSD17B10 Q99714 1/20 0.33
DPP4 P27487 1/20 0.33
ADRA2A P08913 1/20 0.33
GAA P10253 2/20 0.32
MAPT P10636 1/20 0.32
ITGB1 P05556 4/20 0.32
ITGAV P06756 4/20 0.32
P2RX7 Q99572 1/20 0.32
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
SORT1 Q99523 1/20 0.31
KMT2A Q03164 1/20 0.31
ITGB3 P05106 1/20 0.31
ITGA5 P08648 1/20 0.31
ITGA4 P13612 1/20 0.31
ITGB5 P18084 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3310101 1.00 CLCN2 (0.33) CLCN2KDM4EALDH1A1HSD17B10DPP4
SCHEMBL3310104 1.00 CLCN2 (0.33) CLCN2KDM4EALDH1A1HSD17B10DPP4
SCHEMBL3313930 0.85 ALDH1A1 (0.36) CLCN2KDM4EALDH1A1HSD17B10GAA
SCHEMBL3313934 0.85 ALDH1A1 (0.36) CLCN2KDM4EALDH1A1HSD17B10GAA
SCHEMBL3310035 0.78 CLCN2 (0.33) CLCN2ADRA2AGAAMAPTP2RX7
SCHEMBL3310026 0.78 CLCN2 (0.33) CLCN2ADRA2AGAAMAPTP2RX7
SCHEMBL3310032 0.78 CLCN2 (0.33) CLCN2ADRA2AGAAMAPTP2RX7
SCHEMBL3829091 0.78 DPP4 (0.50) CLCN2KDM4EALDH1A1HSD17B10DPP4
SCHEMBL8261361 0.74 GAA (0.37) CLCN2KDM4EALDH1A1HSD17B10DPP4
SCHEMBL1164172 0.74 ALDH1A1 (0.48) CLCN2KDM4EALDH1A1HSD17B10DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8664255-B2 Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof THE TEXAS A&M UNIVERSITY SYSTEM (US) 2014-03-04 US claimed
US-20140171444-A1 Inhibitors of Mycobacterium Tuberculosis Malate Synthase, Methods of Making and Uses Thereof THE TEXAS A&M UNIVERSITY SYSTEM (US) 2014-06-19 US disclosed
US-8664255-B2 Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof THE TEXAS A&M UNIVERSITY SYSTEM (US) 2014-03-04 US disclosed
US-20100113477-A1 Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof TEXAS A&M UNIVERSITY SYSTEM, THE 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113477-A1 Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof ME3, ME1, MDH1 CLCN2 4235/4885KDM4E 1397/4885ALDH1A1 620/4885
US-20140171444-A1 Inhibitors of Mycobacterium Tuberculosis Malate Synthase, Methods of Making and Uses Thereof ME3, ME1, MDH1 CLCN2 4235/4885KDM4E 1397/4885ALDH1A1 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.